Higher Plasma Kynurenine to Tryptophan Correlates with an Increased Incidence of Mild Cognitive Impairment in Treated Metabolic Syndrome Patients
Issued Date
2025-12-30
Resource Type
eISSN
24701343
Scopus ID
2-s2.0-105026215978
Journal Title
ACS Omega
Volume
10
Issue
51
Start Page
63226
End Page
63237
Rights Holder(s)
SCOPUS
Bibliographic Citation
ACS Omega Vol.10 No.51 (2025) , 63226-63237
Suggested Citation
Jariyasopit N., Phochmak T., Manocheewa S., Wanichthanarak K., Limjiasahapong S., Kleebkomut N., Sirivatanauksorn Y., Sirivatanauksorn V., Phrommintikul A., Chattipakorn N., Chattipakorn S., Khoomrung S. Higher Plasma Kynurenine to Tryptophan Correlates with an Increased Incidence of Mild Cognitive Impairment in Treated Metabolic Syndrome Patients. ACS Omega Vol.10 No.51 (2025) , 63226-63237. 63237. doi:10.1021/acsomega.5c09713 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113799
Title
Higher Plasma Kynurenine to Tryptophan Correlates with an Increased Incidence of Mild Cognitive Impairment in Treated Metabolic Syndrome Patients
Corresponding Author(s)
Other Contributor(s)
Abstract
An increase in cognitive impairment was observed in metabolic syndrome (MetS) patients. Although alterations in metabolomic profiles have been identified as potential plasma/serum biomarkers of mild cognitive impairment (MCI) and MetS, findings remain inconsistent─probably due to the heterogeneity among MetS patients and the lack of subsequent validation using targeted analysis after the initial untargeted analysis. In this study, we validated mass spectrometry-based quantitation methods and quantified amino acids, fatty acids, and tryptophan metabolites in the kynurenine pathway in the plasma of 95 treated MetS patients with and without MCI assessed by the Montreal Cognitive Assessment. We found that MCI was positively associated with the kynurenine-to-tryptophan ratio (KTR) after the adjustment for age, gender, and BMI, as well as negatively associated with C20:3 [all-Z-8,11,14] and lysine. A one-unit increase in KTR resulted in an increased probability of developing MCI by 371%. In contrast, one-unit increases in C20:3 and lysine were associated with decreased odds of developing MCI by 81 and 78%, respectively. Our finding underscores prominent neuroinflammation, beyond normal aging, in MetS patients, even under ongoing clinical treatment. It also points to the potential of KTR as a risk marker for MCI, offering a valuable complement to the existing cognitive assessments that may be influenced by the educational background. In addition, the validated metabolite data serve as an invaluable resource for future research. They can facilitate comparisons across different studies, contribute to large-scale analyses, and be used in machine learning models for discovering and validating new biomarkers.